Hyperferritinemia and oxidative stress in the kidney of beta thalassemia major

Dian Ariningrum , Purwanto Adhipireno, Lisyani Budipradigdo Suromo

Dian Ariningrum
Clinical Pathology Department, Medical Faculty, Sebelas Maret University/ Dr. Moewardi Hospital at Surakarta, Central Java, Indonesia. Email: dianariningrum@staff.uns.ac.id

Purwanto Adhipireno
Clinical Pathology Department, Medical Faculty, Diponegoro University at Semarang, Central Java, Indonesia

Lisyani Budipradigdo Suromo
Clinical Pathology Department, Medical Faculty, Diponegoro University at Semarang, Central Java, Indonesia
Online First: August 01, 2019 | Cite this Article
Ariningrum, D., Adhipireno, P., Suromo, L. 2019. Hyperferritinemia and oxidative stress in the kidney of beta thalassemia major. Bali Medical Journal 8(2). DOI:10.15562/bmj.v8i2.1413

Background: Thalassemia is a genetic disorder which until now has become a global health problem. Regular blood transfusions in managemen of BTM result in iron overload. Free iron in the form of intracellular ferrous (Fe2+), in the presence of oxygen, will initiate the formation of reactive oxygen species (ROS), produce another free radical superoxide that will oxidize the lipid and protein compounds of the cell membrane. F2-IsoPs is the best, most stable and more accurate marker of lipid peroxidation in vivo, found urine. This study aimed to determine the association between hyperferritinemia and lipid peroxidation in kidney reflected as elevated u-F2IsoPs as controlling several factors affecting oxidative stress in the kidney.

Methods: This cross sectional study was conducted between May and June 2016. Thirty subjects of BTM admitted to pediatrics unit of Dr. Moewardi Hospital Surakarta who met the inclusion and exclusion criteria were enrolled. The data were analyzed to calculate prevalence ratio and 95%CI for each variable, followed by multivariate analysis with logistic regression.

Results: The prevalence of lipid peroxidation in kidney, characterized with elevated u-F2IsoPs of > 2 ng/mg urine creatinine, was 67%. Age, hyperferritinemia status and duration of illness did not associate with lipid peroxidation in the kidney. Transfusion volume of ≥25 unit/year showed statistically significant association with lipid peroxidation (PR 24.10; 95%CI 2.16-268.42; p=0.010).

Conclusion: Transfusion volume, rather than hyperferritinemia, independently associated to oxidative stress and lipid peroxidation of the kidney in BTM.


Atmakusumah TD, Setyaningsih I. Dasar-dasar talasemia: salah satu jenis hemoglobinopati. dalam: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati, S. Buku Ajar Ilmu Penyakit Dalam. 5th ed. Jakarta, 2009:16.

Langlois S, Jason C, Cithayat D. Carrier Screening for Thalassemia and Hemoglobinopathies in Canada. SOGC-CCMG Clinical Practice Guidelines. 2008; 218:950-9.

Rund D, Rachmilewitz E. β Thalassemia. N Engl J Med. 2005; 353:1135‒46.

Chiou SS, Chang TT, Tsai SP, Jang RC, Lin SK, Lee SC, Tsai SM, Tsai LY. Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection. Clin Chem. 2006; 44(10):1226-1233.

Rodak BF, Fritsma GA, Keohane EM. Hematology: Clinical Principles and Applications. 4th ed. Elsevier Saunders. St. Louis. 2012:261-263,391-396.

Vinita B, Hrishikesh B, Sarika M, Sandip L. Oxidative stress in patients with β thalassemia major. Int J of Recent Trends in Sci Tech. 2015; 15(1):65-7.

Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006; 52(4):601-23.

Janicka M, Kot-Wasik A, Kot J, Namieśnik J. Isoprostane’s biomarkers of lipid peroxidation: their utility in evaluating oxidative stress and analysis. IJMS. 2010; 11:4631-59.

Rahman T, Hosen I, Islam T, Shekhar HU. Oxidative stress and human health. Advances Biosci Biotech. 2012;3:997-1019.

Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT Jr. Wintrobe’s Clinical Hematology. 13th ed. Philadelphia: Lippincott Williams & Wilkins. 2014: 1096-1097.

Piga A, Fracchia S, Maria EL, Maria DC, Raimund H, Antje W, Forni GL, et al. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia. Br J Haematol. 2015; 168:882–90.

Bakr A, Al-Tonbary Y, Osman G, El-Ashry R. Renal complications of β‒thalassemia major in children. Am J Blood Res. 2014; 41:1-6.

Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2‒isoPs as direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002; 25(3):537-41.

Anonim. 8-Isoprostane EIA Kit. Ann Arbor. Cayman Chemical. 2014:1-36.

Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, et al. Oxidative stress and inflammation in iron-overloaded patients with ß-thalassemia or sickle cell disease. Br J. Haematol. 2006; 135:254–63.

Matayatsuk C, Lee CYJ, Kalpravidh RW, Sirankapracha P, Wilairat P, Fucharoen S, Halliwell B. Elevated F2-isoprostanes in thalassemic patients. Free Radic Biol Med. 2007; 43:1649-55.

Ziyadeh FN, Musallam KM, Mallat NS, Mallat S, Jaber F, Mohamed AA, Koussa S, et al. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-Thalassemia Intermedia. Nephron Clin Pract. 2012; 121:136-43.

Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multi-transfused patients with beta-thalassemia. Annals of Haem. 2016; 95(3):375-381.

Gokce M, Kup H, Tugcu D, Salcioglu Z, Aydogan G, Akcay A, Akici F. Insidious renal damage in patients with thalassemia major: Is it more serious than appreciated? J Hematol Thrombo Dis. 2014; 2(6)1-4.

Lai ME, Spiga A, Vasquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β-thalassemia major: a long-term follow-up study. Nephrol Dial Transplant. 2012; 27:3547-3551.

Brenner BM, Lawyer EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996; 49:1774-1777.

Kell DB, Pretorius E, Serum Ferritin is an Important Inflammatory Disease Marker, as It Mainly a Leakage Product from Damaged Cells, Metallomics. 2014;6:748-773.

Puliyel M, Sposto R, Berdoukas VA et al. Ferritin Trends Do Not Predict Changes in Total Body Iron in Patients with Transfusional Iron Overload. Am J Hematol. 2014; 89:391-394.

Cabantchik ZI, Labile Iron in Cells and Body Fluids: Physiology, Pathology, and Pharmacology. Frontiers in Pharmacology. 2014; 5(45):1-11.

Cappellini MD, Cohen A, Porter J, et al., Editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd edition. Nicosia (CY): Thalassaemia International Federation. 2014.

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0